Incyte makes bid to join the checkpoint inhibitor club

Incyte makes bid to join the checkpoint inhibitor club

Submitted by admin on February 2, 2021 - 10:25am
Source: 
Pharmaforum
News Tags: 
Incyte
FDA
retifanlimab
anal cancer
HIV
HPV
Headline: 
Incyte makes bid to join the checkpoint inhibitor club
snippet: 

Incyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal cancer associated with human papillomavirus (HPV) and HIV infections.

Do Not Allow Advertisers to Use My Personal information